W Phillip Niemeyer Net Worth

The estimated Net Worth of W Phillip Niemeyer is at least $445 millier dollars as of 11 June 2007. W Niemeyer owns over 30,000 units of Artelo Biosciences Inc stock worth over $71,400 and over the last 18 years W sold ARTL stock worth over $373,950.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

W Niemeyer ARTL stock SEC Form 4 insiders trading

W has made over 7 trades of the Artelo Biosciences Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently W exercised 30,000 units of ARTL stock worth $88,500 on 11 June 2007.

The largest trade W's ever made was exercising 35,000 units of Artelo Biosciences Inc stock on 29 May 2007 worth over $103,250. On average, W trades about 15,000 units every 4 days since 2007. As of 11 June 2007 W still owns at least 60,000 units of Artelo Biosciences Inc stock.

You can see the complete history of W Niemeyer stock trades at the bottom of the page.

What's W Niemeyer's mailing address?

W's mailing address filed with the SEC is 901 Janesville Ave, Fort Atkinson, WI 53538, USA.

Insiders trading at Artelo Biosciences Inc

Over the last 21 years, insiders at Artelo Biosciences Inc have traded over $1,017,062 worth of Artelo Biosciences Inc stock and bought 94,621 units worth $215,565 . The most active insiders traders include Connie Matsui, Steven B Lapin et Georgia Erbez. On average, Artelo Biosciences Inc executives and independent directors trade stock every 89 days with the average trade being worth of $13,026. The most recent stock trade was executed by Gregory D. Gorgas on 12 August 2022, trading 1,200 units of ARTL stock currently worth $4,800.

What does Artelo Biosciences Inc do?

artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.

Complete history of W Niemeyer stock trades at Artelo Biosciences Inc

Artelo Biosciences Inc executives and stock owners

Artelo Biosciences Inc executives and other stock owners filed with the SEC include:

• Gregory D. Gorgas,
  Pres, CEO, CFO, Treasurer, Sec. & Director
• Jason H. Baybutt,
  Sr. VP of Fin.
• Dr. Steven D. Reich,
  Chief Medical Officer
• Peter Michael O'Brien,
  Sr. VP of European Operations
• Dr. Andrew Yates Ph.D.,
  Sr. VP, Chief Scientific Officer & Member of Scientific Advisor Board
• Randy Schreckhise,
  VP of Fin. & Operations
• Donald T Netter,
  Director
• Brian Schlier,
  Vice President
• James G Tatum,
  Director
• John A Whritner,
  Director
• John L Lahey,
  Director
• Ira R Harkavy,
  Director
• Inc. Lrta,,
  10% owner
• Corp /De/Nasco Holdings, In...,
  
• Steven B Lapin,
  President & COO
• H William Smith,
  V.P., Gen. Counsel & Secretary
• W Phillip Niemeyer,
  Vice President-Prod. Coord.
• Dean T Johnson,
  Chief Financial Officer
• Corp /De/ Geneve,
  10% owner
• John Joseph Crawford,
  Director
• Sharon M Oster,
  Director
• Douglas Blayney,
  Director
• Connie Matsui,
  Director
• Peter Michael O'brien,
  
• Steven Kelly,
  Director
• John W Beck,
  
• Georgia Erbez,
  
• Robert Martin Emanuele,
  Director
• Gregory Reyes,
  Director
• Tamara A Favorito,
  Director
• Gregory D. Gorgas,
  Pres, CEO, CFO, Treas & Sec